Fenofibrate News and Research

RSS

Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.

Can a mango a day keep diabetes away?

The study reveals that daily mango consumption may enhance insulin sensitivity and reduce body fat in prediabetic adults, emphasizing whole fruits' advantages.

29 Sep 2025

New insights into screening and treatment for diabetic retinal disease

Diabetes affects more than 1 in 10 adults worldwide and has been accompanied by an increase in vision-threatening diabetic retinal disease.

12 Mar 2025

First-ever clinical trials evaluate fenofibrate as treatment for HPV-related cancers

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC).

28 Feb 2025

Inhibiting S6K2 gene offers potential treatment for drug-resistant melanoma

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

5 Feb 2025

Simple trick supercharges T cells to fight stubborn solid tumors

Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells - an approach known as "cell-based therapy," which uses specially designed T cells to fight cancer.

13 Dec 2023

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Researchers assessed the effect of fenofibrate on acute COVID-19.

9 Nov 2022

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.

8 Nov 2022

Novel drug lowers triglycerides, does not reduce cardiovascular events

Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice.

6 Nov 2022

FDA-approved drug encourages sensory neurons to regrow after injury

A spinal cord injury damages the lines of communication between the body and brain, impeding the signals that drive movement and sensation.

18 Oct 2021

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

The SARS-CoV-2 virus has infected over 165 million people worldwide causing nearly 3.5 million deaths. Recent vaccination efforts have been hindered by multiple coronavirus variants that challenge current vaccines.

23 Aug 2021

Eldelumab and Fenofibrate show potential for COVID-19

In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19.

10 Jun 2021

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

About 60 percent of drugs on the market have hydrophobic molecules as their active ingredients. These drugs, which are not soluble in water, can be difficult to formulate into tablets because they need to be broken down into very small crystals in order to be absorbed by the human body.

8 Jun 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.

22 Dec 2020

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

Intensive interventions to reduce blood glucose and blood pressure levels in type 2 diabetes reduce the risk of developing cardiovascular autonomic neuropathy (CAN), a frequent but underdiagnosed complication of diabetes that can be life-threatening.

17 Dec 2020

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Materials scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a new pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease (PD).

16 Sep 2020

Cholesterol-lowering drugs show promise to lower COVID-19's threat

Could a simple drug, that has been on the market for decades, be used to treat COVID-19? A research team led by Hebrew University of Jerusalem (HU)'s Professor Yaakov Nahmias says that early research looks promising; their findings appear in this week's Cell Press' Sneak Peak.

15 Jul 2020